אונקולוג מומחה בסרטן דרכי העיכול

front3


ד"ר אפרים אידלביץ



ד"ר אפרים אידלביץ MD, PhD.
אונקולוג מומחה.
מנהל היחידה לגידולי מערכת העיכול, מרכז רפואי קפלן.
מנהל היחידה אונקולוגית קופת החולים לאומית.
אונקולוג יועץ מרכז רפואי סרג'יקר.
אונקולוג יועץ קופות החולים כללית, מכבי ומאוחדת.

רשימת פרסומים

1. Idelevich E, Huszar M, Fenig E, Brenner B, Ben Baruch N, Shani A.
Diagnostic dilemmas in oncology.
Umbilacal metastasis as presenting symptom of non small cell lung cancer.
J Clin Oncol 2000,18:3188-3189

2. Idelevich E.
Surgical treatment of varicosis of lower extremities and brief hospitalization Medical and economic effectiveness of the method.
Med Abs J,
Moscow, 1985,10: 4; 5-6 (in English)

3. Vasutcov V, Idelevich E
Comparative evaluation of treatment methods for post-thrombophlebitic syndrome.
Long-term results.
Cardiology, Moscow, 1988, 6: 111-112

4. Zusman I, Zusman R, Korol D, Sandler B, Smirnoff P, Bass D, Shani A, Idelevich E, Huszar M, Tendler Y, Glick J.
Antihuman-TAA-Antibodies can isolate p53 antigen from the serum of cancer patients and can be used as a new tool for colon cancer diagnosis.
Hum Antibod Hybridomas
1996,7: 123-128

5. Zusman I, Sandler B, Gurevich P, Zusman R, Smirnoff P, Tendlr Y, Bass D, Shani A, Idelevich E, Pfefferman R, Davidovich B, Huszar M, Glick J.
Comparative study of the role of serum levels of p53 antigen and its tumor cell concentration in colon cancer detection.
Hum Antibod Hybridomas
1996, 7: 118-123

6. Zusman I, Zusman R, Sandler B, Gurevich P, Smirnoff P, Bass D,Or A, Shani A, Idelevich E.
Gel fiberglass as a new matrix of affinity chromatography columns for isolation of colon cancer-associated antigens.
Int J Oncol 1996,9: 153-157

7. Zusman I, Zusman R, Sandler B, Korol D, Gurevich P, Smirnoff P, Bass D, Or A, Shani A, Idelevich E, Huszar M, Tendler Y, Klein T Shezen E, Glick J.
PLC determination of serum of soluble p53 antigen as a method for colon cancer detection, and its clinical implication.
Int J Oncol
1996, 8: 1249-1256.

8. Sandler B Smirnoff P, Idelevich E Shani A, Pfefferman R, Davidovich B, Zusman R, Zusman I.
The role of soluble p53 antigen and its autoantibodies as markers for diagnosis of colon cancer. A comparative study.
Int J Molecular Med 1998, 1:453-457

9. Sandler B, Smirnoff P, Shani A, Idelevich E, Kaganski N, Pfeffermann R, Davidovich B, Zusman I.
The role of blood levels of soluble 53 kDa protein and CEA in monitoring cancer patients.
Anticancer Res 1999,19:4229-4233

10. Fenig E, Idelevich E, Njuguna E, Katz A, Gutman H, Sulkes A,
Schechter J.Role of radiation therapy in the management of cutaneous malignant melanoma.
Am J Clin Oncol 1999,22: 184-186

11. Brenner B, Sulkes A, Rakowsky E, FeinmesserM, Yukelson A, Bar-Haim E, KatzA, Idelevich E, Neuman A, Barhana M, Fenig E.
Second neoplasms in patients with Merkel cell carcinoma.
Cancer 2001, 91: 1358-1362

12. Brenner B, Fried G, Levitzki P, Rakowsky E, Lurie H, Idelevich E, Neuman A, Kaufman B, Sulkes A.
Male breast carcinoma in Israel.
Cancer 2002,15: 2128-2133

13. Idelevich E, Mozes M, Ben-Baruch N, Huszar M, Kruglikova A, KatsnelsonR, Shani A.
Oncogens in male breast cancer. Am J Clin Oncol
2003, 26: 259-261

14. Idelevich E , Man S, Lavrenkov K, Gluzman A, Geffen B, Shani A.
Irinotecan combined with bolus 5-FU and folinic acid for Metastatic Colorectal Cancer.
Is this really a dangerous treatment?
J Chemotherapy 2004, 16: 487-490

15. Yerushalmi R, Idelevich E, Dror Y, Stemmer SM, Figer A, Sulkes A, Brenner B, Loven D, Dreznik Z, Nudelman I, Shani A, Fenig E.
Preopertaive chemoradiation in rectal cancer: retrospective comparison between capecitabine and continuous infusion of 5-FU.
J Surg Oncol, 2006 Jun 1; 93(7):529-533 16. Idelevich E, Kashtan H, Mavor E, Brenner B.
Small bowel obstruction caused by secondary tumors (review article).
Surgical Oncology, 2006, volume 15, issue1: 29-32.

17. Idelevich E, Karminsky N, Dinerman M, Katsenelson R, Ben Zvi N, Ben Baruch N, Biran H, Man S, Shani A.
A phase II study of cisplatin, epirubicin, UFT, and Leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
Acta Oncol. 2007; 46(3): 324-329.

18. N.F. Aykan, E. Idelevich.
The role of UFT in advanced gastric cancer. Review.
Annals of Oncology 2008; 19: 1045-1052.

19. Idelevich E, Buyevich V, Machlenkin S, Ziv- Sokolvsky N, Dinerman M, Brenner B, Kashtan H.
Overall survival with cisplatin and 5-Fluorouracil neoadjuvant treatment in patients with esophageal cancer: single-center experience.
Onkologie 2008; 31(12): 673-677.

20. Idelevich E, Greif F, Mavor E, Miller R, Kashtan H, Susmalian S, Ariche A, Ben Baruch N, Dinerman M, Shani A. Phase II study of UFT with Leucovorin plus hepatic arterial infusion with Irinotecan, 5-Fluorouracil and Leucovorin for non-resectable liver metastases of colorectal cancer.
Chemotherapy. 2008;
55(2): 76-82.

21. Machlenkin S, Melzer E, Idelevich E, Ziv-Sokolovsky N, Klein Y, Kashtan H.
Endoscopic ultrasaound: doubtful accuracy for restaging esophageal cancer after preoperative chemotherapy.
Isr Med Assoc J. 2009 Mar;11(3):166-169.

22. Warman M, Halperin D, Poria Y, Huszar, Idelevich E.
Tumor: successful therapy for tumor in a unique Nasopharyngeal carcinoid location.
Otolaryngology-Head and Neck Surgery (OTO-HNS) 2009; 140(3) 437-438.

23. Shemesh-Bar L, Kundel Y, Idelevich E, Sulkes J, Sulkes A, Brenner B. Colorectal cancer in young patients in Israel – a distinct clinicopathological
entity? World J Surgery. 2010; 34(11): 2701-2709.

24. Pines G, Klein Y, Buyeviz V, Idelevich E, Kashtan H.
Disease-related mortality within the first year after subtotal esophagectomy.
Ann Surg Oncol. November 2010.

25. Yulia Kundel, M.D. Ronen Brenner, M.D. Ofer Purim, M.D. Nir Peled, M.D. Efraim Idelevich, M.D. Eyal Fenig, M.D.Aaron Sulkes, M.D. Baruch Brenner, M.D.
Is Local Excision After Complete Pathological Response to Neoadjuvant Chemoradiation for Rectal Cancer an Acceptable Treatment Option?
"Disease of the Colon & Rectum"
Volum 53: 12 (2010)

26. Pines G, Klein Y, Melzer E, Idelevich E, Bueviz V, Machlenkin S, Kashtan H.
One hundred transhiatal esophagectomies: a single-institution experience.
Isr Med Assoc J. Vol 13: 428-433.

27. Kundel Y, Purim O, Idelevich E et al.
Postopertaive chemoradiation for resectable gatsric cancer-is the Macdonald regimen tolerable? A retrospective multi- institutional study.
Radiat Oncol. 2011 Sep 29; 6:127-131.

28. Dreznik A, Purim O, Idelevich E et al.
Gastric cancer: biology and clinical manifestations in Israel.
J Surg Oncol. 2011 Aug 31. doi: 10.1002/jso.22078

29. Goldberg N, Kundel Y, Purim O, Gordon N, Bernstine H, Morgenstern S, Idelevich E, Vasserberg N, Sulkes A, Groshar D, Brener B.
Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18F-FDG PET-CT imaging. A prospective clinical study.
Radiat Oncol, 2012; 7(1):124-130.

30. Prospective phase II study of neoadjuvant therapy with cisplatin, 5-fluorouracil' and bevacizumab for locally advanced resectable esophageal cancer.
Idelevich E, Kashtan H, Klein Y, Buevich V, Baruch NB, Dinerman M, Tokar M, Kundel Y, Brenner B.
Onkologie. 2012; 35(7-8): 427-431.

31. Ethnic variation in toxicity and outcome of adjuvant chemoradiation for gastric cancer in Israel.
Brenner RM, Kivity S, Kundel Y, Purim O, Peled N, Idelevich E, Lavrenkov K, Kovel S, Fenig E, Sulkes A, Brenner B.
Anticancer Res. 2013 Nov;33(11):5151-7
PMID:24222163[PubMed – indexed for MEDLINE]

PARTICIPATIONS IN SCIENTIFIC CONFERENCES

1. Conference of Molecular Biology, UK, 1996 Abstract presentation:
Zusman IPI, Zusman RPI, Korol DC, Sandler BC, Smirnoff PC, Bass DC, Or AC, Shani AC, Idelevich EC, Glick JC, Tendler YC.
Serum level of the soluble p53
protein as a marker for colon cancer diagnosis. In: Proceedings of the abstracts of Oncology,
1996:9, 825-826

2. 8th International p53 Workshop,1996 Abstract prsentation:
Zusman IPI, Zusman RPI, Korol DC, Sandler BC, Gurevich PC, Smirnoff PC, Bass DC, Or AC, Shani AC, Idelevich EC, Huszar MC, Tendler YC, Glick JC.
The role of the cytoplasmic p53 protein as serological marker for early Detection of colon cancer in humans. Abstracts of 8th International
p53 Workshop, 1996, 116

3. Israel Society of Clinical Oncology and Radiotherapy (ISCORT) Annual Meeting, 2002
Oral presentation and abstract:
Idelevich E, Mozes M, Ben-Baruch N, Huszar M, Kruglicova A, Katsnelson R, Shani A.
Molecular markers in male breast cancer.
In: Proceedings of ISCORT,
2002, abstr 609

4. Israel Society of Clinical Oncology and Radiotherapy (ISCORT) Annual Meeting, 2002
Oral presentation and abstract:
Idelevich E, Greif F, Kori Y, Shani A.
Adjuvant hepatic arterial infusion plus systemic chemotherapy after curative resection of hepatic metastases from colorectal cancer.
In: Proceedings of ISCORT,
2002, abstr 708

5. Israel Society of Clinical Oncology and Radiotherapy (ISCORT)
Annual Meeting, 2002
Abstract presentation:
Ben-Baruch NPI, Idelevich EC, Ben-zvi NC, Kruglikova AT, Dgani RC, Shani AC
Weekly Taxoter/Carboplatin (TC) in previously treated patients with recurrent ovarian cancer.
In: Proceedings of ISCORT,
2002, abstr 227

6. Israel Society of Clinical Oncology and Radiotherapy (ISCORT) Annual Meeting, 2002
Abstract presentation:
Ben-Zvi NPI Kruglikova AT, Idelevich EC, Katsnelson RC, Biran HC, Dinerman MC, Shani AC, Ben-Baruch NPI.
Vinorelbin, 5FU and Leucovorin is moderately active, well tolerated regimen in patients with metastatic breast cancer.
In: Proceedings of ISCORT,
2003, abstract 501.

7. Israel Society of Clinical Oncology and Radiotherapy (ISCORT)
Annual Meeting, 2002
Abstract presentation:
Ben-Baruch NPI, Idelevich EC, Ben-Zvi NC, Kruglicova AT, Shani AC.
Weekly Taxoter/Gemcitabine (TG) + Hercepton (H) in previously treated patients with metastatic breast cancer.
A highly effective, low toxicity regimen.
In: Proceedings of ISCORT, 2002, abstr 370.

8. American Society of Clinical Oncology (ASCO)
Annual Meeting, 2003
Presentation of abstract:
Idelevich EPI, Ben-Baruch N, Katsnelson R, Dinerman M, Ben-Zvi N, Shani A.
Single institution experience of Irinotecan and 5FU bolus with Leucovorin (IFL Saltz regimen) for metastatic colorectal cancer.
Is it really dangerous treatment?
Proceedings of ASCO (Am Soc Clin Oncol) 22:
2003, abstract 1195

9. Israel Society of Clinical Oncology and Radiotherapy (ISCORT)
Annual Meeting, 2004
Oral presentation and abstract:
Idelevich EPI, Greif F, Mavor A, Shani
A Hepatic arterial infusion (HAI) with Irinotecan, 5FU, and Folinic Acid (FA) in combination with UFT/FA chemotherapy for unresectable liver metastases of colorectal cancer.
In: Proceedings of ISCORT, 2004, abstract 505

10. Israeli Society of Clinical Oncology and Radiotherapy (ISCORT) Annual
Meeting, 2004
Oral presentation and abstract:
Idelevich EPI, Man S, Figer A, Shani A. First-line Capecitabine monotherapy for advanced colorectal cancer.
In: Proceedings of ISCORT,
2004, abstr. 506

11. American Society of Clinical Oncology (ASCO)
Annual Meting 2004.
Abstract presentation:
Cohen Y, Shulman K, Idelevich E, Ben-Shachar , Honnigman J, Haiat H, Zidan J, Hubert A, Kuten A, Beny A.
Irinotecan (CPT-11)
Combined with UFT as first line treatment of advanced colorectal carcinoma – A phase II study.
Proceeding of ASCO:
2004, abstract 3742, 304s

12. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer
Symposium. Poster presentation.
Idelevich E, Greif F, Mavor E, Shani A.
Hepatic arterial infusion (HAI) with irinotecan, 5-FU, and folinic acid in For unresectable liver metastases of colorectal cancer.
2006, abstract 377.

13. Journal of Clinical Oncology
2006, ASCO Abstract presentation
Idelevich E, Karminsky N, Dinerman M, Ketsenelson R, Ben Zvi N, Ben Baruch N, Man S, Shani A.
Phase II study of cisplatin, epirubicin, oral UFT, and leucovorin as first-line chemotherapy for metastatic gastric cancer.
Annual Meeting
proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 14049.

14. 8-th World Congress on Gastro intestinal Cancer,
July 2006, Poster presentation
Kundel Y, Idelevich E, Purim O,Kovel S, Karminsky N, Pfefer R, Catane R, Nisinbaum B, Stemmer S, Fenig E, Sulkis A, Brenner B.
Postoperative Chemoradiation for resected gastric cancer- is the MacDonald regimen tolerable?

15. Annals of Oncology
2007, ESMO Poster presentation
Purim O, Brenner B, Idelevich E, Gutman H, Feinmesser, Ben Yosef R, Marshak G, Abramovich A, Sulkes A, Fenig E.
Merkel cell carcinoma in Israel- a retrospective analysis of 76 consecutive patients.
Ann Oncol, 2007,
volum 18, Supplement 9, 99 PD, ix 188-ix 189.

16. European Journal of Nuclear Medicine and Molecular Imaging,
2006, Poster presentation
Pinkas L, Simonovsky V, Shani A, Idelevich E.
Single institution experience with Sandostatin treatment of metastatic neuroendocrine tumors.
European J of Nuclear Medicine,
2006, volum 33, supplement 2, p 258.

17. Merck Serono Symposium,
Darmstadt, Germany, March 16-17,2007,
UFT (tegafur-uracil) in gastrointestinal cancer.
Oral presentation (lecture): UFT in metastatic gastric cancer.

18. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer
Symposium, 2008. Abstract presentation
Purim O, Dreznik A, Kundel Y, Idelevich E, Abramovich A, Stemmer S, Fenig E, Sulkes B, Brenner B.
Gastric Cancer in Israel – a retrospective analysis Of 461 consecutive patients over 12 year period.

19. ESMO conference Lugano
( European Society of medical Oncology) 3-6 July 2008.
Annals of Oncology, volum, 19, supplement 5, 41PD.
Poster presentation.
R. Brenner, Kundel Y, Idelevich E, Abramovich A, Purim O, Peled N, Nisenbaum B, Fenig E, Sulkes A, Brenner B.
Restaging after preopertaive chemoradiation for rectal cancer – can it actually predict histological response to treatment?

20. ESMO Internatioanl Symposium:
10-th World congress on Gastrointestinal Cancer, 25-28 June, 2008: Barcelona.
Annals of Oncology, volum 19, supplement 6, p-285, vi101.
Poster presentation. Brenner B, Shemesh-bar L, Purim O, Kundel Y, Idelevich E, Abramovich A, Sulkes A, Brenner B.
Colorectal cancer in young Patients in Israel – a unique clinicopathological entity?

21. 1st Russian Federation Symposium of Neuro-endocrine tumors. November 2009.
Moscow, Central Institute of Oncology of Russian Federation,
Oral presentation.
Lecture: Neuro-endocrine Tumors: current concepts of diagnosis and treatment.

22. 3d Ukraine Annual Conference of Endocrinology "ENDOWEEK-2009", December 2009. Kiev.
Oral presentation.
Lecture: Neuro-endocrine Tumors: current concepts of diagnosis and treatment.

23. 4th Ukraine Conference of Surgical Oncology, June 2010, Kiev.
Colorectal cancer in young patients in Israel – a distinct clinicopathological entity? World J Surgery. 2010; 34(11): 2701-2709.

24. Disease-related mortality within first year after subtotal esophagectomy for cancer
3rd World Cancer Congress "Health Science without Borders", June 2010,
Singapore.
Oral presentation.
Lecture: Overall survival with cisplatin and 5-FU neoadjuvant treatment in atients with esophageal cancer: single-center experience.

25. 9th international Gastric Cancer Congress (IGCC 2011), April 2011, Soul, Korea
Oral presentation.
Lecture: Phase II study of Erbitux, Cisplatin, Epirubisin, UFT with Leucovorin (E-PELUF) as neoadjuvant treatment in patients with Gastric Cancer.

26. International Symposium "Surgical treatment of colorectal liver metastases", June 2011, Moscow, Russia.
Oral presentation.
Lecture: The multimodal treatment of colorectal liver metastases.

27. BIT's 5th Annual World Cancer Congress, May 2012, Beijing, China
Oral presentation.
Lecture: Neoadjuvant therapy in esophageal cancer: comparison between cisplatin plus 5-fluorouracil with or without bevacizumab.